UNSPSC 51313602: Repirinast

This classification denotes a histamine-1 receptor antagonist with the molecular formula C20H21NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4K8KA8B61G, chemically known as 4h-pyrano(3,2-c)quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, isopentyl ester but generally known as repirinast, which bears US NIH Compound Identifier 5050. European Medicines Agency schedules Repirinast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10281MIG.

UNSPSC 51313602 Repirinast, a Commodity code, nominally names a specific pharmaceutical compound, but recent state and local solicitations tagged under this code do not reflect purchases of repirinast itself. Instead, issuing bodies are buying naloxone (opioid-reversal medication), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing frameworks. The work spans direct product procurement by county health departments, multi-state cooperative purchasing alliances, and state health and human services commissions seeking to establish drug-supply contracts with manufacturers and wholesalers. Issuing bodies include Seminole County (Florida) health operations and state-level agencies such as the Texas Health and Human Services Commission and the Minnesota Department of Administration, often acting through cooperative purchasing vehicles like MMCAP (Minnesota Multistate Cooperative Purchasing Alliance) to aggregate demand across multiple jurisdictions and participating states.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County issued an IFB (IFB60459723LAS, due July 26, 2023, posted June 30, 2026) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, requiring vendors to cover shipping and include drug-free workplace and E-Verify compliance. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels, designed to inform future RFP development rather than award contracts immediately. The Minnesota Department of Administration, via MMCAP, issued an RFP (S1070000015802, due March 26, 2026) for multi-state generic pharmaceutical and OTC product supply contracts across participating state and local government facilities, with awarded vendors effective July 1, 2026, requiring cGMP and Drug Supply Chain Security Act certification, relationships with authorized wholesalers, and pricing flexibility across multiple formats. The code shows limited relevant recent activity, with the three posted opportunities representing exploratory market-intelligence and direct-supply contracting rather than repirinast-specific procurement.